



Threat of mpox (Monkeypox) Outbreak after the COVID-19 Pandemic: Are Healthcare Professionals Ready for New Psychological Wars?

COVID-19 Salgını Sonrası mpox (Maymun Çiçeği) Salgını Tehdidi: Sağlık Çalışanları Yeni Psikolojik Savaşlara Hazır Mı?

✉ Mehmet Çelik¹, ✉ Ufuk Acar², ✉ Fethiye Akgül³, ✉ Yusuf Arslan³, ✉ Mehmet Reşat Ceylan¹

¹Harran University Faculty of Medicine Department of Infectious Diseases and Clinical Microbiology, Şanlıurfa, Turkey

²Harran University Faculty of Medicine Department of Public Health, Şanlıurfa, Turkey

³Batman Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Batman, Turkey

Abstract

Aims: In this study, it was aimed to evaluate the psychological status of healthcare professionals regarding the COVID-19 pandemic, and to examine their perspectives and knowledge levels regarding the mpox epidemic.

Material and Method: Having a cross-sectional design, the present study was carried out by using questions addressing sociodemographic characteristics of healthcare professionals, their experiences with the COVID-19 pandemic, and their knowledge and anxiety levels regarding mpox.

Results: 202 healthcare professionals were involved in the present study. Of the participants, 55% were female and the mean age was 35.0±7.7 years. The majority (63.4%) of the participants were midwives/nurses/medical assistants. Of the participants, 68.8% were infected by COVID-19 during the pandemic. Considering the questions addressing their level of knowledge about mpox, 44.1% of participants stated that they had never heard of this disease before. Participants were found to have mainly moderate levels of depression and anxiety and low level of stress, whereas the ratios of very severe depression and anxiety were 5.0% and 7.4%, respectively.

Conclusion: It was determined that almost half of the participants had no full knowledge of the disease before the increase in mpox cases. It was found that the participants varying levels of depression, anxiety, and stress about a new pandemic. We think that it is important to provide healthcare professionals with psychosocial support, make effort in order to determine and eliminate the sources of psychological negativities.

Keywords: Anxiety, COVID-19, depression, monkeypox, mpox

Öz

Amaç: Bu çalışmada, sağlık çalışanlarının COVID-19 pandemisine ilişkin psikolojik durumlarının değerlendirilmesi, mpox salgınına bakış açılarının ve bilgi düzeylerinin incelenmesi amaçlandı.

Gereç ve Yöntem: Kesitsel bir tasarıma sahip olan bu çalışma, sağlık çalışanlarının sosyodemografik özellikleri, COVID-19 pandemisi ile ilgili deneyimleri ve mpox'a ilişkin bilgi ve kaygı düzeylerini ele alan sorular kullanılarak gerçekleştirildi.

Bulgular: Çalışmaya 202 sağlık çalışanı dahil edildi. Araştırma kapsamına alınanların %55'i kadını ve yaş ortalaması 35.0±7.7 yılı. Katılımcıların büyük çoğunluğu (%63.4) ebe/hemşire/sağlık memuruydu. Katılımcıların %68.8'i pandemi sırasında COVID-19 ile enfekte oldu. Mpox ile ilgili bilgi düzeylerine yönelik yöneltilen sorularda katılımcıların %44.1'i (n=89) bu hastalığı daha önce hiç duymadıklarını ifade etti. Katılımcıların ağırlıklı olarak orta düzeyde depresyon ve anksiyete ile düşük düzeyde strese sahip olduğu, çok şiddetli depresyon ve anksiyete oranlarının ise sırasıyla %5.0 ve %7.4 olduğu bulundu.

Sonuç: Çalışmada katılımcıların neredeyse yarısının mpox vakalarındaki artıştan önce hastalık hakkında tam bilgiye sahip olmadığı belirlendi. Katılımcıların yeni bir pandemiye karşı farklı düzeylerde depresyon, kaygı ve stres yaşadıkları tespit edildi. Psikolojik olumsuzlukların kaynaklarının belirlenip ortadan kaldırılması için sağlık çalışanlarına psikososyal destek verilmesinin, çaba gösterilmesinin önemli olduğunu düşünüyoruz.

Anahtar Kelimeler: Anksiyete, COVID-19, depresyon, maymun çiçeği, mpox

Corresponding (İletişim): Mehmet Çelik, Harran University Faculty of Medicine Department of Infectious Diseases and Clinical Microbiology, Şanlıurfa, Turkey

E-mail (E-posta): dr.mcelik12@gmail.com

Received (Geliş Tarihi): 23.06.2023 **Accepted (Kabul Tarihi):** 17.07.2023



INTRODUCTION

On 11 March 2020, coronavirus disease-2019 (COVID-19) was announced as a global pandemic by the World Health Organization (WHO).^[1] The disease spread out to more than 220 countries worldwide. At the global scale, the number of cases reached 767 million and deaths to 6.9 million.^[2] Developing due to SARS-CoV-2, COVID-19 is carried between humans through droplets. Healthcare professionals are at risk because of their contact with patients and social transmission.^[3] It was reported that this increase in the risk to catch the virus for healthcare professionals during the pandemic increased the anxiety of becoming ill and might cause burnout for both these professionals and their families/friends.^[4]

The new outbreak caused by the monkeypox virus (MPXV) while the world is still struggling with the COVID-19 pandemic increased the anxiety of healthcare officials that this disease might be a new threat.^[5,6] Caused by MPXV, mpox (formerly known as monkeypox disease) is a zoonotic infection and is widely seen in Central and Western Africa. The first mpox case in humans was reported in Democratic Kongo Republic in the year 1970.^[7,8] Contagion of MPXV to humans occurs via direct contact with an infected human or animal or through materials contaminated with the virus.^[9]

Although MPXV has been in circulation for years where it is endemic, mpox studies have been ignored and the studies on this subject have not been funded sufficiently.^[10] In May 2022, multiple mpox cases were detected in several non-endemic countries.^[11] On 23 July 2022, WHO declared the mpox as a "Global Emergency".^[12] As of the date 6 June 2023, 87,929 mpox cases and 146 deaths were reported from 111 countries worldwide. It is seen that the number of cases has decreased on a global scale since August 2022, and on May 10 2023, WHO declared mpox is no longer a global emergency.^[13]

The increasing number of human mpox cases indicates the importance of protection from the disease, early diagnosis, and epidemic management. Besides that, in a report prepared by the WHO, it was reported that one of the difficulties in preventing the outbreak of mpox was the lack of information about mpox, especially among healthcare professionals.^[7,14] In this study, it was aimed to evaluate the psychological status of healthcare professionals regarding the COVID-19 pandemic, and to examine their perspectives and knowledge levels regarding the mpox epidemic.

MATERIAL AND METHOD

Ethical Approval and Permissions

The study was carried out with the permission of Harran University Clinical Researches Ethics Committee (Date: 08.08.2022, Decision No: HRÜ/22.15.20). All procedures were carried out in accordance with the ethical rules and the principles of the Declaration of Helsinki.

Study Design and Subjects

The universe of this study consists of all the healthcare professionals working in different branches and at different positions in administration and service departments of Batman Training and Research Hospital. The data were collected between August 2022 and November 2022. Without using a sampling method, all the volunteer healthcare professionals were involved in this study. The present study was completed with 202 participants. The healthcare professionals (55 professionals), who were not volunteer in participating in the study, were excluded (Participation ratio: 78.6%).

Data Collection Tools

The study data were collected using a survey that consists of 4 sections. The first section of the survey consists of 9 items addressing the sociodemographic characteristics and comorbidity, whereas the second section consists of 7 items examining their professional and personal experiences during the COVID-19 pandemic. While the third section consists of 19 items investigating their level of knowledge and anxiety about mpox, the fourth section consists of the "Depression, Anxiety, and Stress Scale-2021 (DASS-21)" developed in order to determine the depression, anxiety, and stress disorder levels of participants. Developed by Lovibond P. F. and Lovibond S. H., the Depression Anxiety Stress Scale (DASS) consists of 42 items.^[15] It was revised into its 21-item short form (DASS-21) by Sariçam H.^[16] The scale includes 3 subdimensions, each of which consists of 7 items, addressing depression, anxiety, and stress. The scale is rated between 0 (never) and 3 (always) in order to determine the depression, anxiety, and stress levels in the last week. Cronbach's Alpha internal consistency coefficient of the scale was found to be 0.87 for depression, 0.85 for anxiety, and 0.81 for stress. In this study, the DASS-21 scale's internal consistency Cronbach alpha coefficient was found to be 0.85 for depression, 0.80 for anxiety, and 0.77 for stress and considered to be at a sufficient level.

Statistical Methods

The data obtained were analyzed using IBM SPSS Statistics v.22.0 (IBM Corp.; Armonk, NY, USA) package software. During the statistical analyses, mean \pm standard deviation and minimum-maximum values were used for continuous variables, whereas numbers and percentages were used for nominal variables. Continuous variables' fitness to normal distribution was tested using the Shapiro-Wilk test, normal distribution diagrams, and skewness and kurtosis coefficients. The significance of differences for continuous variables was examined using independent samples t-test and F-test (One-way ANOVA). The level and direction of relationships between two numerical variables were analyzed using Pearson's correlation analysis. For all the analyses, statistical significance was set at $p < 0.05$.

RESULTS

In total, 202 healthcare professionals were involved. Of the participants, 55.0% (n=111) were women and the mean age was found to be 35.0±7.7 (min-max=22-57) years. The portion of married participants was 67.3% (n=136) and the mean number of children was 2.4±1.3 (min-max=1-5). The highest portion of participants (63.4%, n=128) consisted of midwives /nurses/medical assistants, while the mean duration of employment was 11.8±7.6 (min-max=1-37) years. It was determined that 77.7% (n=157) of the participants have worked in departments, where COVID-19-related services were offered, during the pandemic (**Table 1**).

Table 1. Participant's sociodemographic characteristics and their experiences with the COVID-19 pandemic

Characteristics	n (%)
Gender	
Female	111 (55.0)
Male	91 (45.0)
Age [Mean ±SD (Min-Max)]	35.0±7.7 (22-57)
Marital status	
Non-married	66 (32.7)
Married	136 (67.3)
Number of children [Mean ±SD (Min-Max)]	2.4±1.3 (1-5)
Position	
Specialist physician/Physician	32 (15.8)
Midwife/Nurse/Medical assistant	128 (63.4)
Other supporting medical personnel	26 (12.9)
Administration and service personnel	16 (7.9)
Professional employment time [Mean ±SD (Min-Max)]	11.8±7.6 (1-37)
Active workplace during the pandemic	
Pandemic-related units	157 (77.7)
Units that are not related with the pandemic	45 (22.3)
Chronic physical disorder	
No	174 (86.1)
Yes	28 (13.9)
Chronic mental disorder	
No	197 (97.5)
Yes	5 (2.5)
Diagnosed with COVID-19	
No	63 (31.2)
Yes	139 (68.8)
Family member diagnosed with COVID-19	
No	30 (14.9)
Yes	172 (85.1)
Loss of a family member due to COVID-19	
No	183 (90.6)
Yes	19 (9.4)
COVID-19 diagnosis in social circle	
No	5 (2.5)
Yes	197 (95.5)
Death by COVID-19 in social circle	
No	50 (24.8)
Yes	152 (75.2)
Colleague diagnosed with COVID-19	
No	3 (1.5)
Yes	199 (98.5)
Loss of a colleague due to COVID-19	
No	144 (71.3)
Yes	58 (28.7)
Vaccination against COVID-19	
No	23 (11.4)
Yes	179 (88.6)
Number of COVID-19 vaccine doses [Mean ±SD (Min-Max)]	2.8±1.4 (0-6)
Side effects after COVID-19 vaccine	
No	150 (74.3)
Yes	52 (25.7)

The COVID-19 infection ratio among the participants during the pandemic was 68.8% (n=139), whereas the same ratio was found to be 85.1% (n=172), 95.5% (n=197), and 98.5% (n=199) for their family members (spouse, parents, children, etc.), social circle (relatives, friends, etc.), and colleagues, respectively. The ratios of COVID-19-related death were found to be 9.4%, 75.2%, and 28.7% for family members, social circle, and colleagues, respectively. The ratio of participants, who moved from the place they have been actively living before the pandemic during the pandemic period, was 26.2% (n=53). The ratio of participants that have been vaccinated for COVID-19 was 88.6% (n=179) (**Table 1**).

In questions addressing the level of knowledge about mpox, 44.1% (n=89) stated that they had never heard about this disease before. Of the participants, 46% (n=93) had accurate information about the cause of the disease, 54% (n=109) had accurate information about the infection pathway, and 35.6% (n=72) had accurate information about the places, where the disease is endemic to. While 24.3% (n=49) were informed about the smallpox vaccine, the response of 48.0% (n=97) of the participants to the question if the smallpox vaccine is protective against mpox was "yes" (**Table 2**).

Table 2. Participant's knowledge and attitudes about mpox

Characteristics	n (%)
Having knowledge about mpox before the announcement of WHO*	
No	89 (44.1)
Yes	113 (55.9)
Having knowledge about the cause of mpox	
No information	104 (51.5)
Wrong information	5 (2.5)
Accurate information	93 (46.0)
Having knowledge about the mode of transmission of mpox	
No information	53 (26.2)
Wrong information	40 (19.8)
Accurate information	109 (54.0)
Having knowledge about risky contact time for mpox	
No knowledge	174 (86.1)
Accurate knowledge	28 (13.9)
Having knowledge about regions, where mpox is endemic	
No knowledge	66 (32.7)
Wrong information	64 (31.7)
Accurate information	72 (35.6)
Having knowledge about protection measurements against mpox	
No information	100 (49.5)
Accurate information	102 (50.5)
Having knowledge about diagnosis methods for mpox	
No information	9 (4.5)
Wrong information	93 (46.0)
Accurate information	100 (49.5)
Having knowledge about treatment methods for mpox	
No	128 (63.4)
Yes	74 (36.6)
Having knowledge about the Mpox vaccine	
Wrong information	153 (75.7)
Accurate information	49 (24.3)
Having knowledge about the protectiveness of the smallpox vaccine	
No	105 (52.0)
Yes	97 (48.0)

*WHO: World Health Organization

DAS-21, a standard measurement tool, was used to determine the psychological state of healthcare workers trying to meet the increasing healthcare needs with the COVID-19 pandemic, in case of a possible new pandemic [16]. The mean total score of the scale was found to be 12.68±11.16 (min-max=0-46), whereas the mean scores in depression, anxiety, and stress subdimensions were 4.55±4.15 (min-max=0-19), 3.34±3.48 (min-max=0-14), and 4.79±4.07 (min-max=0-16), respectively. Besides that, the portions of participants in the regions, which were classified between mild to extremely severe by the developer, for depression, anxiety, and stress were 46.6%, 40.1%, and 22.7% (Table 3). It was determined that the participants generally had moderate level of depression and anxiety and mild level of stress, whereas the portions of participants having extremely severe depression and anxiety were 5.0% and 7.4%, respectively.

The distribution of participants' mean scores by their sociodemographic characteristics, their experiences with COVID-19 pandemic, and knowledge about mpox are presented in Table 4. The participants, who had a chronic psychological disorder, in the total scale and in all subdimensions were found to be statistically significantly higher mean scores (p<0.05). The COVID-19 vaccine caused a significant change in the

mean scores (p<0.05). Those not having knowledge about the diagnosis and treatment of mpox were found to have significantly higher mean scores in the total scale and in all subdimensions (p<0.05).

Table 3. Correlation analysis and categorical distribution of the participant's scores in the DASS-21 scale and its subdimensions

Variables	x ±SD (Min-Max)	1	2	3
1 Depression	4.55±4.15 (0-19)	1	0.834 (<0.001)	0.886 (<0.001)
2 Anxiety	3.34±3.48 (0-14)		1	0.871 (<0.001)
3 Stress	4.79±4.07 (0-16)			1
Total score	12.68±11.16 (0-46)	0.955 (<0.001)	0.940 (<0.001)	0.966 (<0.001)
Pearson's correlation analysis, r(p)				
Category	Depression, n (%)	Anxiety, n (%)	Stress, n (%)	
Normal	108 (53.4)	121 (59.9)	156 (77.3)	
Mild	35 (17.3)	25 (12.4)	18 (8.9)	
Moderate	39 (19.3)	26 (12.9)	14 (6.9)	
Severe	10 (5.0)	15 (7.4)	14 (6.9)	
Extremely severe	10 (5.0)	15 (7.4)	-	

Table 4. Distribution of various characteristics of participants by the mean scores in DASS-21 total scale and subdimensions

Characteristics	DASS-21 Mean±SD	DASS-21D Mean±SD	DASS-21A Mean±SD	DASS-21S Mean±SD
Gender				
Male	10.43±10.54	4.03±4.02	2.48±3.29	3.91±3.80
Female	14.52±11.37	4.98±4.21	4.04±3.49	5.50±4.15
t	-2.630	-1.624	-3.223	-2.813
p	0.009	0.106	0.001	0.005
Age groups				
20-29 years	15.42±11.50	5.53±4.30	4.18±3.53	5.70±4.32
30-39 years	11.69±11.17	4.23±4.09	2.98±3.56	4.49±4.08
40 years and older	11.28±10.46	4.02±3.96	2.98±3.21	4.28±3.67
F	2.632	2.453	2.558	2.219
P	0.074	0.089	0.080	0.111
Marital status				
Non-married	15.95±12.36	6.18±4.67	4.09±3.79	5.68±4.54
Married	11.09±10.21	3.76±3.63	2.97±3.27	4.35±3.76
t	2.960	4.027	2.162	2.196
p	0.003	<0.001	0.032	0.029
Having child				
No	15.90±11.44	5.94±4.15	4.17±3.54	5.79±4.42
Yes	10.65±10.53	3.69±3.92	2.81±3.36	4.15±3.71
t	3.330	3.881	2.727	2.839
p	0.001	<0.001	0.007	0.005
Active workplace during the pandemic				
Pandemic-related units	13.42±11.43	4.84±4.11	3.52±3.64	5.06±4.17
Units that are not related to the pandemic	10.09±9.88	3.56±4.15	2.69±2.81	3.84±3.57
t	1.774	1.842	1.418	1.771
p	0.078	0.067	0.158	0.078
Chronic physical disorder				
No	12.01±10.89	4.36±4.03	3.12±4.43	4.53±3.92
Yes	16.82±12.14	5.75±4.69	4.68±3.52	6.39±4.63
t	-2.134	-1.649	-2.217	-2.272
p	0.034	0.101	0.028	0.024
Chronic mental disorder				
No	12.18±10.66	4.38±4.01	3.17±3.29	4.63±3.91
Yes	32.40±13.95	11.40±3.84	10.00±4.63	11.00±5.78
t	-4.157	-3.862	-4.535	-3.554
p	<0.001	<0.001	<0.001	<0.001
Infection diagnosis				
No	10.17±10.10	3.81±11.47	2.70±3.27	3.67±3.64
Yes	13.81±11.47	4.89±4.31	3.63±3.54	5.29±4.16
t	-2.165	-1.726	-1.761	-2.673
p	0.032	0.086	0.080	0.008

Table 4. Distribution of various characteristics of participants by the mean scores in DASS-21 total scale and subdimensions

Characteristics	DASS-21 Mean±SD	DASS-21D Mean±SD	DASS-21A Mean±SD	DASS-21S Mean±SD
Infection diagnosis in the family				
No	11.07±11.45	4.33±4.07	2.93±3.68	3.80±4.11
Yes	12.96±11.12	4.59±4.17	3.41±3.45	4.96±4.05
t	-0.856	-0.316	-0.686	-1.443
p	0.393	0.753	0.493	0.151
Loss of a family member due to the infection				
No	12.63±11.43	4.55±4.27	3.30±3.50	4.79±4.17
Yes	13.11±8.42	4.58±2.73	3.74±3.33	4.79±2.91
t	-0.175	-0.038	-0.525	-0.004
p	0.861	0.970	0.600	0.997
Infection diagnosis in the social circle				
No	8.60±12.64	2.80±4.08	2.80±4.38	3.00±4.24
Yes	12.78±11.14	4.60±4.15	3.35±3.47	4.83±4.06
t	-0.826	-0.957	-0.348	-0.994
p	0.410	0.340	0.728	0.321
Death caused by infection in the social circle				
No	12.38±11.77	4.42±4.34	3.28±3.78	4.68±4.20
Yes	12.78±11.00	4.60±4.09	3.36±3.39	4.83±4.04
t	-0.217	-0.263	-0.132	-0.214
p	0.828	0.792	0.895	0.831
Infection diagnosis among colleagues				
No	18.33±18.03	6.00±6.24	5.67±6.65	6.67±5.85
Yes	12.59±11.08	4.53±4.13	3.30±3.43	4.76±4.05
t	0.883	0.607	1.168	0.805
p	0.378	0.545	0.244	0.422
Loss of a colleague due to infection				
No	11.47±10.16	4.14±3.83	3.02±3.14	4.31±3.64
Yes	13.17±11.54	4.72±4.27	3.47±3.61	4.98±4.22
t	-0.979	-0.905	-0.826	-1.057
p	0.329	0.367	0.410	0.292
Vaccinated for Covid-19				
No	7.04±7.74	2.00±2.33	2.00±2.46	3.04±3.25
Yes	13.40±11.34	4.88±4.22	3.51±3.56	5.01±4.11
t	-3.485	-4.968	-2.603	-2.641
p	0.001	<0.001	0.013	0.013
Having knowledge about mpox before WHO's announcement				
No	11.74±10.94	4.27±4.14	2.98±3.44	4.49±3.86
Yes	13.42±11.33	4.78±4.15	3.62±3.50	5.02±4.23
t	-1.058	-0.865	-1.302	-0.907
p	0.291	0.388	0.194	0.366
Having knowledge about the cause of mpox				
No information	13.18±11.31	4.74±4.19	3.46±3.62	4.98±3.98
Wrong information	12.40±9.81	4.20±3.56	4.20±3.56	4.00±2.91
Accurate information	12.13±11.15	4.37±4.15	3.15±3.34	4.61±4.23
F	0.218	0.217	0.351	0.294
P	0.804	0.805	0.705	0.745
Having knowledge about mpox's mode of transmission				
No information	13.83±11.40	5.04±4.19	3.62±3.78	5.17±4.05
Wrong information	12.48±11.44	4.43±4.20	3.25±3.49	4.80±4.21
Accurate information	12.19±11.01	4.37±4.12	3.23±3.35	4.60±4.05
F	0.389	0.488	0.241	0.352
P	0.678	0.615	0.786	0.704
Having knowledge about the regions mpox is endemic to				
No information	14.55±12.90	4.95±4.74	3.95±3.95	5.64±4.72
Wrong information	11.86±9.87	4.55±3.82	2.88±3.09	4.44±3.60
Accurate information	11.69±10.45	4.19±3.85	3.18±3.31	4.32±3.73
F	1.379	0.575	1.683	2.172
p	0.254	0.563	0.189	0.117
Having knowledge about protective measurements against mpox				
No information	13.52±11.56	4.88±4.33	3.56±3.52	5.08±4.23
Accurate information	11.85±10.75	4.24±3.95	3.12±3.45	4.50±3.90
t	1.061	1.104	0.902	1.012
p	0.290	0.271	0.368	0.313
Having knowledge about diagnosis methods for mpox				
No information (1)	22.44±14.80	7.67±5.09	6.33±5.12	8.44±5.50
Wrong information (2)	14.00±11.48	5.03±4.32	3.77±3.52	5.19±4.15
Accurate information (3)	10.57±9.90	3.83±3.72	2.66±3.09	4.08±3.64
F	6.177	4.850	6.256	5.875
P	0.002	0.009	0.002	0.003
Post hoc test (Tukey HSD)	(1-3)	(1-3)	(1-3)	(1-2), (1-3)
Having knowledge about the protectiveness of the smallpox vaccine				
No	14.46±12.03	5.16±4.61	3.93±3.72	5.36±4.20
Yes	10.75	3.90±3.49	2.69±3.09	4.16±3.84
t	2.401	2.208	2.586	2.105
p	0.017	0.028	0.010	0.037

t: Independent sample t-test, F: One-Way ANOVA

Some potential and psychiatric variables for the participants after the introduction of mpox into WHO's agenda and the news about the increases in case numbers and the changes in total scale and subdimensions are presented in **Table 5**. The anxiety of transmitting the infection to the family-social circle caused a significant increase in the mean total score and in the mean scores of all subdimensions ($p < 0.05$). Considering the period

after learning about the increase in the number of cases, statistically significant increases were found in the mean scores in the anxiety subdimension for participants reporting a loss of appetite, in total scale, depression, and anxiety subscales for those reporting sleep problems, and in total scale and all subdimensions for those reporting stomach problems ($p < 0.05$).

Table 5. Distribution of participant's opinions about mpox by DASS-21 total scale and subdimensions

Characteristics	DASS-21 Mean±SD	DASS-21D Mean±SD	DASS-21A Mean±SD	DASS-21S Mean±SD
Anxiety of being infected				
Never/Very rarely	10.23±10.65	3.72±3.96	2.49±3.24	4.02±3.95
Sometimes	12.46±11.54	4.49±4.16	3.35±3.43	4.62±4.38
Mostly	14.87±10.88	5.30±4.20	4.00±3.62	5.58±3.72
F	2.327	3.024	2.452	2.807
P	0.100	0.051	0.089	0.063
Anxiety of not being able to be treated				
Never/Very rarely	10.55±9.89	3.84±3.75	2.56±2.95	4.15±4.76
Sometimes	13.18±11.15	4.65±4.02	3.65±3.59	4.88±4.11
Mostly	14.77±12.39	5.35±4.67	3.93±3.83	5.49±4.33
F	2.437	2.985	1.775	2.190
p	0.090	0.053	0.172	0.115
Anxiety of having contact with a foreign national				
Never/Very rarely (1)	7.78±9.31	2.81±3.45	1.88±2.77	3.09±3.55
Sometimes (2)	14.91±11.06	5.37±4.23	4.02±3.48	5.52±3.98
Mostly (3)	14.53±11.42	5.20±4.21	3.88±3.63	5.45±4.13
F	8.438	7.690	7.610	7.570
P	<0.001	<0.001	<0.001	<0.001
Post hoc test (Tukey HSD)	(1-2), (1-3)	(1-2), (1-3)	(1-2), (1-3)	(1-2), (1-3)
Thinking that personal hygiene principles would not be enough				
Never/Very rarely	15.05±11.06	5.31±4.09	4.07±3.43	5.67±4.06
Sometimes	12.58±11.17	4.69±3.99	3.23±3.68	4.67±4.20
Mostly	11.83±11.17	4.21±4.23	3.11±3.41	4.51±4.00
F	1.273	1.097	1.202	1.266
P	0.282	0.336	0.303	0.284
Anxiety of transmitting the infection to family/social circle				
Never/Very rarely (1)	8.47±9.32	3.25±3.79	2.08±2.70	3.15±3.39
Sometimes (2)	13.62±11.58	4.76±4.07	3.76±3.68	5.10±4.27
Mostly (3)	14.58±11.33	5.21±4.27	3.80±3.61	5.57±4.05
F	5.464	3.895	4.890	6.372
p	0.005	0.022	0.008	0.002
Post hoc test (Tukey HSD)	(1-2), (1-3)	(1-3)	(1-2), (1-3)	(1-2), (1-3)
Loss of appetite after learning about the increase in the number of cases				
Never/Very rarely (1)	12.02±10.95	4.37±4.10	3.05±3.31	4.60±4.07
Sometimes (2)	17.59±11.27	6.00±4.25	5.27±3.80	6.32±3.67
Mostly (3)	13.67±14.29	4.50±4.72	4.50±5.08	4.67±5.00
F	2.488	1.508	4.459	1.760
p	0.086	0.224	0.013	0.175
Post hoc test (Tukey HSD)			(1-2)	
Sleep problems after learning about the increase in the number of cases				
Never/Very rarely (1)	11.89±10.84	4.31±4.06	3.03±3.30	4.56±4.02
Sometimes (2)	18.69±10.26	6.44±3.65	5.44±3.28	6.81±3.71
Mostly (3)	20.33±16.69	7.00±6.29	7.00±5.65	6.33±5.20
F	4.313	3.075	7.368	2.751
p	0.015	0.048	<0.001	0.066
Post hoc test (Tukey HSD)	(1-2)	(1-2)	(1-2), (1-3)	
Stomach problems after learning about the increase in the number of cases				
Never/Very rarely (1)	11.24±10.38	4.12±3.93	2.76±3.05	4.35±3.95
Sometimes (2)	21.36±11.80	7.32±4.50	6.55±3.87	7.50±3.78
Mostly (3)	18.10±13.37	5.90±4.67	6.00±4.69	6.20±4.39
F	10.087	6.706	16.824	6.827
p	<0.001	0.002	<0.001	0.001
Post hoc test (Tukey HSD)	(1-2)	(1-2)	(1-2), (1-3)	(1-2)

t: Independent sample t-test, F: One-Way ANOVA

DISCUSSION

It is known that healthcare professionals had remarkable stress during previous pandemics. It was reported that healthcare professionals were emotionally affected during the recent SARS pandemic.^[17,18] Various studies showed that healthcare professionals were at risk of psychiatric disorders due to various reasons during the COVID-19 pandemic.^[19-22] In a previous meta-analysis carried out by Mahmud et al.^[23] the prevalence of depression, anxiety, stress, and sleeplessness among healthcare professionals was reported to be 37.1%, 41.4%, 44.9%, and 43.8%. In a meta-analysis by Li et al.^[24] on 65 studies carried out on 97,333 healthcare professionals from 21 countries, the pooled prevalence of depression was found to be 21.7% and that of anxiety to be 22.1%. Of 202 healthcare professionals involved in the present study, it was determined that 77.7% have worked in departments offering services related to COVID-19, 68.8% were infected by COVID-19 during the pandemic, and infection and COVID-19-related death ratios of family members, social circle, and colleagues were reported to be (85.1%-9.4%), (95.5%-75.2%), and (98.5%-28.7%), respectively. In this study, the DASS-21 scale was used in determining the psychological conditions of healthcare professionals considering the possibility of a new pandemic. Accordingly, the ratios of participants found to have depression, anxiety, and stress were 46.6%, 40.1%, and 22.7%. The ratios of extremely severe depression and anxiety were calculated to be 5% and 7.4%. Among the participants, women had higher anxiety and stress levels in comparison to men ($p=0.001$ - $p=0.005$). The participants, who worked in departments offering services related to COVID-19 during the pandemic, were found to have higher depression, anxiety, and stress levels but the difference was not statistically significant. In comparison to participants, who have not been diagnosed with COVID-19, the participants diagnosed with COVID-19 were found to have statistically significantly higher mean scores in the total scale ($p=0.032$) and in the stress subdimension ($p=0.008$). When compared to those not vaccinated for COVID-19, the participants vaccinated for COVID-19 had lower mean scores in the total scale ($p<0.001$). The participants having a chronic psychological disorder were found to have higher mean scores in the total scale and in all subdimensions ($p<0.05$). The participants having chronic physical disorders were determined to have higher mean scores in anxiety and stress subdimensions ($p=0.034$, $p=0.028$, $p=0.024$). In a study carried out on the psychosocial effects of COVID-19 on healthcare professionals in Italy, various factors such as female gender, working as a nurse, working in a hospital, and having contact with COVID-19 patients were found to be predictor determinants.^[25] In a study carried out in China, it was observed that healthcare professionals working at the front line during the pandemic had more anxiety, sleeplessness, and general psychological disorders.^[26] In the present study, the factors such as female gender, COVID-19 history, COVID-19 vaccination, and chronic psychological and physical disorders were found to be the factors related with depression, anxiety, and stress.

In order to prevent disease transmission, healthcare professionals, especially physicians, should rapidly identify new cases, report them, and have knowledge about the clinical symptoms of mpox.^[7] In some of previous studies, it was reported that healthcare professionals did not have sufficient information about mpox. In a survey study carried out on physicians, pharmacists, nurses, medical technicians, and dentists in Jordan, only 4 of 11 questions about mpox were answered accurately at a higher level than 70% and the knowledge level of physicians about mpox was found to be higher than other groups. In the same study, 33.3% of the participants stated that the smallpox vaccine might be protective against mpox and 58.7% stated that homosexuality was an important factor in the spread of the disease.^[27] In another study carried out in Italy, 27% of the participants stated that they knew mpox before, whereas 58.6% thought that the smallpox vaccine was effective against mpox.^[28] In a study carried out in Indonesia, it was reported that practicing physicians had a very low level of knowledge about mpox and only 10% of them had a sufficient level of knowledge.^[7] In the present study, 44.1% of participants stated that they had never heard about mpox before the announcements of WHO, while 46% of participants had accurate information about the cause of the disease, 54% had accurate information about the infection pathway, and 35.6% had accurate information about the regions, where the disease is endemic. Moreover, 24.3% of the participants were aware of the smallpox vaccine, while the ratio of those thinking that the smallpox vaccine was protective against mpox was 48%. The data indicating the clinical efficiency of the smallpox vaccine against mpox (85%) were reported in surveillance studies on pandemics in Central Africa in the 1980s and in following years and these data were supported by animal studies.^[29] The data obtained here showed that the healthcare professionals' knowledge of mpox before the pandemic was at very low level and this finding is consistent with the literature.

The declaration of a possible mpox outbreak by WHO during the COVID-19 pandemic created an uncertain anxiety state disorder. In a society-based study carried out in Saudi Arabia, it was shown that the participants infected by COVID-19 before had more anxiety about mpox.^[30] In the present study, examining the somatic and psychiatric changes in participants in relation to declarations made by WHO and international media organs about the increase in mpox cases, it was found that anxiety of transmitting the disease to family members or social circle and anxiety of contacting with foreign nationals caused a significant increase in mean depression, anxiety, and stress scores, whereas there were significant increases in mean anxiety score among the participants reporting a loss of appetite, in mean depression and anxiety scores among those reporting sleeplessness, and mean depression, anxiety, and stress scores of those reporting stomach problems. Accordingly, it can be stated that an idea of a potential pandemic might have negative psychological and physiological effects on healthcare

professionals. Moreover, it was determined in the present study, regarding the subdimensions about information on mpox (having prior information about the disease, factors, mode of transmission, incubation period, endemic regions, etc.), there was no difference between the participants having information and those having no information. It might indicate that psychological and physiological effects occurred independently. In order to eliminate the negative effects of the idea of a potential pandemic after the COVID-19 pandemic, it might be useful to provide healthcare professionals with psychosocial support at specific intervals, make effort to eliminate the factors that might cause anxiety, stress, and depression, and use suitable motivation instruments. In the past, it is important to keep the motivation of healthcare professionals, who will be at the front line in potential pandemics in the future, at maximum level.

The present study has also limitations. The main limitations are that the present study was carried out in a single hospital and that participants had limited capacity to present the universe. Moreover, since the predictable numbers couldn't be reached, no assessment could be made about profession-specific knowledge, experience, awareness, and psychology. Besides that, although it is a standard measurement instrument, there might be qualitative errors due to self-reported data since depression, anxiety, and stress conditions of healthcare professionals cannot be confirmed using a clinical assessment. Determining the potential changes in the medical labor force in order to meet the acute medical needs of a society in cases such as a pandemic. For this reason, it is thought that the results achieved here would be useful for policymakers.

CONCLUSION

The COVID-19 pandemic created many negative results among healthcare professionals, from both physiological and psychological aspects. Various factors such as increasing workload during the pandemic, high potential of catching the disease, and anxiety of transmitting the infection to family members and social circle might cause negative effects on healthcare professionals. The increase in mpox cases between May and August of 2022 raise the question if healthcare professionals are physically and mentally ready for a new pandemic. It was determined that, after the increase in the number of mpox cases, almost half of the participants had no complete information about the disease at any dimension (diagnosis, transmission, treatment, protection, etc.). In the present study carried out aiming to determine the psychological condition in case of a new pandemic, it was determined that depression, anxiety, and stress levels of the participants were high. Many somatic and psychiatric changes were observed among healthcare professionals, such as anxiety of transmitting the infection to family members or social circle, contacting with foreign nationals, loss of appetite, sleep problems, and dyspeptic complaints. It is thought

that providing healthcare professionals, who are at the front line in pandemics, with psychosocial support, make effort to determine and eliminate other factors causing negative psychological effects, and use suitable motivational instruments..

ETHICAL DECLARATIONS

Ethics Committee Approval: The study was carried out with the permission of Harran University Clinical Researches Ethics Committee (Date: 08.08.2022, Decision No: HRÜ/22.15.20).

Informed Consent: All patients signed the free and informed consent form.

Referee Evaluation Process: Externally peer-reviewed.

Conflict of Interest Statement: The authors have no conflicts of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

Author Contributions: All of the authors declare that they have all participated in the design, execution, and analysis of the paper, and that they have approved the final version.

REFERENCES

1. World Health Organization [Internet]. Director-General's opening remarks at the media briefing on COVID-19. 2020. [Cited 2020 Apr 9]. Available from: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020>
2. World Health Organization [Internet]. Coronavirus (COVID-19) Dashboard. 2023. [Cited 31 May 2023]. Available: <https://covid19.who.int/>
3. Sommerstein R, Fux CA, Vuichard-Gysin D, et al. Risk of SARS-CoV-2 transmission by aerosols, the rational use of masks, and protection of healthcare workers from COVID-19. *Antimicrob Resist Infect Control* 2020;9(1):100.
4. Yumru M. COVID-19 and burnout in health workers. *J Clin Psy* 2020;23(1):5-6.
5. Yang Z. Monkeypox: A potential global threat?. *J Med Virol* 2022;94:4034-4036.
6. Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Correction to: Prevention and Treatment of Monkeypox. *Drugs* 2022;82(12):1343.
7. Harapan H, Setiawan AM, Yufika A, et al. Knowledge of human monkeypox viral infection among general practitioners: a cross-sectional study in Indonesia. *Pathog Glob Health* 2020;114(2):68-75.
8. World Health Organization [Internet]. Monkeypox. 2022. [Cited 3 Aug 2019]. Available from: <https://www.who.int/newsroom/fact-sheets/detail/monkeypox>
9. Focosi D, Novazzi F, Baj A, Maggi F. Monkeypox: an international epidemic. *Rev Med Virol* 2022;32(6):e2392.
10. Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox virus infection in humans across 16 countries—April–June 2022. *N Engl J Med* 2022;387(8):679-691.
11. World Health Organization [Internet]. Monkeypox;2022. [Cited 19 May 2022]. Available from: <https://www.who.int/newsroom/fact-sheets/detail/monkeypox>
12. World Health Organization [Internet]. Second meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the multi-country outbreak of monkeypox. 2022. [Cited 23 July 2022]. [https://www.who.int/news/item/23-07-2022-second-meeting-of-the-international-health-regulations-\(2005\)-\(ihr\)-emergency-committee-regarding-the-multicountry-outbreak-of-monkeypox](https://www.who.int/news/item/23-07-2022-second-meeting-of-the-international-health-regulations-(2005)-(ihr)-emergency-committee-regarding-the-multicountry-outbreak-of-monkeypox).

13. World Health Organization [Internet]. Monkeypox Outbreak:Global Trends. [Cited 6 June 2023]. Available from: https://worldhealthorg.shinyapps.io/mpx_global/
14. World Health Organization [Internet]. WHO Informal Consultation on Monkeypox 2017. Geneva, Switzerland: World Health Organization;2017. p.18.
15. Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the depression anxiety stress scales (DASS) with the beck depression and anxiety inventories. *Behav Res Ther* 1995;33:335-42.
16. Saricam H. The psychometric properties of Turkish version of Depression Anxiety Stress Scale-21 (DASS-21) in health control and clinical samples. *JCBPR* 2018;7(1):19-30.
17. Polat ÖP, Coşkun F. COVID-19 Salgınında sağlık çalışanlarının kişisel koruyucu ekipman kullanımları ile depresyon, anksiyete, stres düzeyleri arasındaki ilişkinin belirlenmesi. *Batı Karadeniz Tıp Derg* 2020;4(2):51-8.
18. Chan AOM, Huak CY. Psychological impact of the 2003 severe acute respiratory syndrome outbreak on health care workers in a medium size regional general hospital in Singapore. *Occup Med (Lond)* 2004;54:190-6.
19. Restauri N, Sheridan AD. Burnout and Posttraumatic Stress Disorder in the Coronavirus Disease 2019 (COVID-19) Pandemic: Intersection, Impact, and Interventions. *J Am Coll Radiol* 2020;17:921-6.
20. Lee AM, Wong JG, McAlonan GM, et al. Stress and Psychological Distress among SARS Survivors 1 Year after the Outbreak. *Can J Psychiatry* 2007;52(4):233-40.
21. Chew NW, Lee GK, Tan BY, et al. A multinational, multicentre study on the psychological outcomes and associated physical symptoms amongst healthcare workers during COVID-19 outbreak. *Brain Behav Immun* 2020;88:559-65.
22. Ghio L, Patti S, Piccinini G, et al. Anxiety, depression and risk of post-traumatic stress disorder in health workers: the relationship with burnout during COVID-19 pandemic in Italy. *Int J Environ Res Public Health* 2021;18:9929.
23. Mahmud S, Hossain S, Muyeed A, Islam MM, Mohsin M. The global prevalence of depression, anxiety, stress, and, insomnia and its changes among health professionals during COVID-19 pandemic: A rapid systematic review and meta-analysis. *Heliyon* 2021;7(7):e07393.
24. Li Y, Scherer N, Felix L, Kuper H. Prevalence of depression, anxiety and posttraumatic stress disorder in health care workers during the COVID-19 pandemic: A systematic review and meta-analysis. *PLoS ONE* 2021;16(3):e0246454.
25. Giusti EM, Pedroli E, D'Aniello GE, et al. The psychological impact of the COVID-19 outbreak on health professionals:a cross-sectional study. *Frontiers in psychology* 2020;11:1684.
26. Que J, Shi L, Deng J, et al. Psychological impact of the COVID-19 pandemic on healthcare workers:a cross-sectional study in China. *Gen Psychiatr* 2020;33(3):e100259.
27. Sallam M, Al-Mahzoum K, Al-Tammemi AB, et al. Assessing HealthcareWorkers' Knowledge and Their Confidence in the Diagnosis and Management of Human Monkeypox: A Cross-Sectional Study in a Middle Eastern Country. *Healthcare* 2022;10:1722.
28. Riccò M, Ferraro P, Camisa V, et al. When a Neglected Tropical Disease Goes Global:Knowledge, Attitudes and Practices of Italian Physicians towards Monkeypox, Preliminary Results. *Trop Med Infect Dis* 2022;7:135.
29. Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines:a rapid review. *The Lancet Infectious Diseases* 2022;22(12):349-58.
30. Temsah MH, Aljamaan F, Alenezi S, et al. Monkeypox caused less worry than COVID-19 among the general population during the first month of the WHO Monkeypox alert:Experience from Saudi Arabia. *Travel Med Infect Dis* 2022;49:102426.